Export controls- “In response thereto, the United States and other North Atlantic Treaty Organizations member states, as well as certain non-member states, announced targeted economic sanctions, embargoes and export controls on Russia and Belarus . The Company’s dependence on distributors located in Russia and Belarus for a significant portion of its turnover puts it at risk of losing revenue due to actual or potential wars involving these countries.”Uncertainties in regulatory and other matters in emerging markets could complicate the Company’s marketing strategy internationally.
- “Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector.”We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, the violation of which can result in serious consequences.
Government customers- “Disruptions at the FDA and other government agencies caused by new administration policies or funding shortages could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.”Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
- “Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities, and recent efforts by the Department of Government Efficiency have brought scrutiny to waste in agency spending, resulting in numerous lawmakers calling for the codification of relevant funding cuts.”Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
- “Disruptions at the FDA and other agencies may also slow the time necessary for new devices to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities, and recent efforts by the Department of Government Efficiency (DOGE) have brought scrutiny to waste in agency spending, resulting in numerous lawmakers calling for the codification of relevant funding cuts.”We are subject to foreign currency risk.
- “We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations.”We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, the violation of which can result in serious consequences.
Revenue, in its own words- “Total revenue increased to $49.17 million in 2025 from $48.38 million in 2024 (+1.6%). Gross profit declined to $34.24 million in 2025 from $34.47 million in 2024, and operating income declined to $0.68 million in 2025 from $3.48 million in 2024.”Key Factors Affecting Our Results of Operations
- “Total revenue increased to $29.32 million in 2026 from $24.22 million in 2025 (+21%). Gross profit increased from $15.02 million for the six months ended June 2025 to $18.27 million for the same period 2026, and experienced an operating loss of $0.77 million for the six months ended June 2025 compared to operating income of $2.10 million for the same period 2026.”Key Factors Affecting Our Results of Operations
- “Total revenue was $48.38 million for the year ended December 31, 2024 compared to $49.17 million for the year ended December 31, 2025, an increase of $0.79 million, or 1.6%. The year-over-year increase was driven primarily by higher volumes in Europe and selected international markets while sales in the U.S. declined due to channel realignment.”Revenue
Quoted from the company's own filing. Read the S-1/A at the SEC